Hua Medicine (Shanghai) Ltd. (HKG:2552)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.650
-0.010 (-0.27%)
Apr 2, 2026, 4:08 PM HKT
Market Cap3.61B +56.4%
Revenue (ttm)548.54M +92.6%
Net Income1.23B
EPS1.22
Shares Out988.01M
PE Ratio2.98
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,071,300
Average Volume4,255,675
Open3.660
Previous Close3.660
Day's Range3.570 - 3.720
52-Week Range1.730 - 4.950
Beta1.11
RSI65.90
Earnings DateMar 26, 2026

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic diseas... [Read more]

Sector Healthcare
Founded 2011
Employees 285
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2552
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements